Korean pharmaceutical and biotech companies have successfully outlicensed new drugs in various fields, including cancer, autoimmune disease, and Alzheimer's disease. However, compared to the year before, analysis suggests that the number of out-licensed cases decreased.

Despite such a slowdown, companies focusing on global new drug development trends, including Alzheimer's disease treatment and antibody-drug conjugates (ADC), have drawn interest from the industry following achieving grand-size contracts.

We analyzed major out-licensing cases from Korean pharmaceutical and biotech companies in 2024 and explored the potential of future out-licensing possibilities for 2025.

Ac